A shadow market for unapproved slimming drugs is being driven by social media fitness personalities and vendors on communication apps, according to recent findings.
Investigational Drug Gaining Traction Via Social Media
Retatrutide, which remains in research studies, is being promoted by online personalities for its supposed fat-burning effects. Followers are encouraged to message these profiles privately for supplier links, while also receiving promotional offers.
Active Commerce on Messaging Platforms
Additionally, a flourishing trade exists on Telegram, where groups with thousands of members share comparison photos, administration instructions and assertions of rapid British shipping. Vendors promote the drug there before redirecting buyers to other platforms for transactions.
Learning About The Experimental Drug
Retatrutide is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Early trials indicate it could assist patients reduce up to a quarter of their body weight. Referred to as the “triple G”, the substance is being hailed digitally as the successor to Ozempic.
Medical Experts Express Concerns
Nevertheless, doctors and chemists have warned that the distribution of what remains an unlicensed drug in the UK is a cause for concern and could result in individuals administering substances of uncertain source.
Several experts stated the demand for retatrutide could be connected to the rising price of approved weight loss treatments such as Mounjaro.
Regulatory Position and Implementation
Selling the unapproved drug on social media or messaging apps is illegal in the United Kingdom, as it is an unlicensed medication that cannot be promoted or distributed for human use under the British medical regulations.
Several content creators try to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and distribution can still breach pharmaceutical, marketing, and consumer regulations, potentially leading to penalties, prosecution or prison.
Platform Response and Content Elimination
Based on the social media company, the service has taken down problematic content and prohibited associated keywords and query recommendations. The organization stated it was committed to maintaining the service secure and investing in strengthening enforcement strategies.
Online Trading Activities
Research also found groups with up to 9,000 members selling retatrutide using Telegram's built-in search feature, which functions like a public directory. Typing “retatrutide” instantly displays groups with thousands of members, populated with images of slimming results, positive reviews and step-by-step guides for preparing or administering at residence.
After moments of entering one group, a seller shared contact information, where most purchases take place. The seller provided an guidebook and guaranteed shipping within 48 hours. When asked whether the substance was genuine, one seller said: “You can’t be sure.” Another provided a image of a supposed testing documentation. None inquired about weight, medical conditions or past usage.
Product Details and Pricing
Inside these groups, posts display black plastic packages with Royal Mail stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, mixed at home with purified liquid, or pre-filled pens usually sold at £160 for 20 milligrams. When asked how long a injector should be used, vendors give conflicting responses varying between a few weeks to “depends on your body”.
Service Moderation and Safety Actions
A spokesperson for the messaging service stated it actively moderated harmful material on its platform including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.
Healthcare Professional Cautions
“People are administering substances they cannot confirm. Even if the research behind retatrutide is sound, these digital products may not include what they claim,” stated a pharmacy expert, the head of pharmaceutical services at Chemist4U.
Dr Crystal Wyllie of an online medical service linked the increase in demand to current cost increases for authorized slimming drugs such as Mounjaro. “With prices rising, individuals are using social media. But counterfeit treatments are highly dangerous. You can’t be certain what’s contained or whether the environment they were produced in was sterile,” she explained.
Her staff has already encountered individuals injured by self-injection from unverified sources. “We understand the disappointment, but purchasing from Telegram or communication platforms is gambling with your health,” said Wyllie. “These materials could be contaminated or incorrectly dosed.”
Manufacturer Position
A spokesperson from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been reviewed or approved by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they explained, adding that any product “falsely representing itself as a company investigational product not yet authorized … may subject patients to possibly serious medical dangers”.
